IP Library Granted Patent US 9,816,135
Granted Patent B2
US 9,816,135 · App. 14/906,636 · Granted Nov 14, 2017

Fluidic cartridge for nucleic acid amplification and detection

Inventors: Thomas Richard Kerby Edwards (Wiltshire, GB); Toby Charles Edward Mullarkey (Wiltshire, GB); Kevin David Neale (Wiltshire, GB); Jay Kendall Taylor (Ottawa, CA); Ben Arlett (Bristol, GB)
Assignee: Atlas Genetics Limited
C12Q1/686B01L3/502B01L3/502738C12Q1/6825G01N27/403B01L7/52B01L2200/10B01L2200/16B01L2300/0645B01L2300/0681B01L2300/0816B01L2300/0867B01L2300/0877B01L2300/0883B01L2400/0481B01L2400/0487B01L2400/06B01L2400/0638B01L2400/0683
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,816,135
App. No.
14/906,636
Granted
Nov 14, 2017
Kind
B2
Abstract

A cartridge for assay of a target nucleic acid sequence in a liquid sample. The cartridge comprises: a fluidic portion through which the sample flows and in which nucleic acid amplification and detection takes place; a pneumatic portion which controls flow through the fluidic portion; and at least two electrodes which provide a potential difference for the detection of an amplified nucleic acid of interest.

Claims (26)

1. A cartridge for assay of a target nucleic acid sequence in a liquid sample comprising a plastic housing enclosing:

a. a plastic fluidic portion comprising a channel fluidly connecting a sample inlet to at least one amplification chamber where nucleic acid amplification can take place; a channel fluidly connecting the amplification chamber to at least one detection chamber where the results of nucleic acid amplification can be electrochemically detected; an exhaust; and a gas inlet connectable to a gas supply which is capable of pushing the sample downstream through the cartridge,

wherein the channels and/or chambers comprise at least one pneumatically controlled valve,

and wherein upstream of the amplification chamber are provided: reagents and/or physical components for cell lysis and nucleic acid separation; in or upstream of the amplification chamber, but downstream of the reagents and/or physical components for cell lysis and nucleic acid separation, are provided reagents for nucleic acid amplification including a nucleic acid polymerase; and in or upstream of the detection chamber, but downstream of the amplification chamber, are provided reagents for electrochemical nucleic acid detection;

b. a plastic pneumatic portion comprising at least one pneumatic pressure inlet and pneumatic circuit for conveying pneumatic pressure;

whereby flow through the channels and chambers can be controlled by the pneumatic pressure applied to the at least one pneumatically controlled valve; and

c. at least two electrodes capable of providing a potential difference across the at least one detection chamber for permitting detection of electrochemically active molecules.

2. The cartridge of claim 1 , wherein the fluidic portion further comprises a control nucleic acid.

3. The cartridge of claim 2 , wherein the control nucleic acid is DNA.

4. The cartridge of claim 1 , wherein the target nucleic acid is DNA.

5. The cartridge of claim 4 , wherein the target DNA is from a pathogen.

6. The cartridge of claim 1 , wherein the reagents for nucleic acid amplification further comprise primers capable of hybridizing to the target nucleic acid sequence, dNTPs, and optionally further comprises one or more of buffer salts, MgCl2, passivation agents, uracil N-glycosylase and dUTP.

7. The cartridge of claim 2 , wherein the reagents for nucleic acid amplification further comprise primers capable of hybridizing to the control nucleic acid.

8. The cartridge of claim 1 , wherein the reagents for electrochemical nucleic acid detection comprise at least one target probe comprising a label, wherein the target probe is capable of specifically hybridizing to the target molecule.

9. The cartridge of claim 2 , wherein the reagents for electrochemical nucleic acid detection comprise at least one control probe comprising a label, wherein the control probe is capable of specifically hybridizing to the control molecule.

10. The cartridge of claim 8 , wherein the label is a ferrocene label.

11. The cartridge of claim 1 , wherein the reagents for nucleic acid detection comprise a 5′ to 3′ exonuclease.

12. The cartridge of claim 1 , wherein the pneumatic portion comprises multiple pneumatic pressure inlets each of which controls flow through separate regions of the fluidic portion.

13. The cartridge of claim 1 , wherein flow through the channels and chambers is controlled by multiple pneumatically controlled valves.

14. The cartridge of claim 1 , wherein the fluidic portion further comprises a coarse filter downstream of the sample inlet and upstream of the reagents and/or physical components for cell lysis and nucleic acid separation.

15. The cartridge of claim 1 , wherein the reagents and/or physical components for cell lysis and nucleic acid separation include lysis buffer.

16. The cartridge of claim 1 , wherein the reagents and/or physical components for cell lysis and nucleic acid separation include a nucleic acid capture column.

17. The cartridge of claim 1 , wherein the fluidic portion further comprises one or more of a sample mixing chamber, a sample indicator, a bellows, a mixing channel, a blister sub-assembly, an isolation valve, an elution chamber.

18. The cartridge of claim 1 , wherein the plastic fluidic portion comprises polypropylene.

19. The cartridge of claim 1 , wherein the plastic pneumatic portion comprises polypropylene.

20. The cartridge of claim 1 , wherein the plastic housing comprises acrylonitrile butadiene styrene.

Assignments (6)
SECURITY INTEREST Recorded Mar 25, 2025
From: BINX HEALTH LIMITED
To: KREOS CAPITAL VII (UK) LIMITED
Reel/Frame 070620/0287 →
RELEASE OF SECURITY INTEREST Recorded Jan 18, 2025
From: BX HEP AGGREGATOR, LLC,
To: BINX HEALTH LIMITED
Reel/Frame 069925/0466 →
ASSIGNMENT OF PATENT SECURITY AGREEMENT Recorded Oct 3, 2024
From: ORBIMED ROYALTY & CREDIT OPPORTUNITIES III, LP
To: BX HEP AGGREGATOR, LLC
Reel/Frame 069107/0116 →
PATENT SECURITY AGREEMENT Recorded Apr 7, 2021
From: BINX HEALTH LIMITED
To: ORBIMED ROYALTY & CREDIT OPPORTUNITIES III, LP
Reel/Frame 055859/0724 →
CHANGE OF NAME Recorded Dec 12, 2019
From: ATLAS GENETICS LIMITED
To: BINX HEALTH LIMITED
Reel/Frame 051264/0447 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 22, 2017
From: EDWARDS, THOMAS RICHARD KERBY; MULLARKEY, TOBY CHARLES EDWARDS; NEALE, KEVIN DAVID; TAYLOR, JAY KENDALL; ARLETT, BEN
To: ATLAS GENETICS LIMITED
Reel/Frame 043357/0854 →
Priority Claims (1)
GB 1313511.6 · Jul 29, 2013 · national
Continuity (1)
Related Publication 20160168624A1 · Jun 16, 2016